Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
3.81 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Zentalis Pharmaceuticals, Inc. |
Symbool | ZNTL |
Munteenheid | USD |
Prijs | 3.81 |
Beurswaarde | 270,921,480 |
Dividendpercentage | 0% |
52-weken bereik | 2.66 - 18.07 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Kimberly Lynn Blackwell M.D. |
Website | https://zentalis.com |
An error occurred while fetching data.
Over Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)